Transverse Medical Inc. Announces Completion of Series B2 Capital Raise
Transverse Medical Inc., a leading innovator in Cerebral Embolic Protection for stroke prevention during TAVR (Transcatheter Aortic Valve Replacements) and early-stage medical device technology company, today announced the successful completion of its Series B2 financing round. The company secured over $10 million in new capital from the Company’s Legacy Lead investor, a large, sophisticated Family Office, which also included participation from the Series B1 investors to complete the round.
Transverse Medical Inc. Announces Completion of First Series of Patients in Feasibility Clinical Study at Victorian Heart Hospital, Melbourne, Australia, Using Point-Guard Cerebral Embolic Protection.
Transverse Medical Inc. is excited to announce the completion of the first series of patients under its Feasibility Clinical Study at the prestigious Victorian Heart Hospital in Melbourne, Australia. The patients undergoing TAVR procedures (Transcatheter Aortic Valve Replacement) were treated using the company's next generation POINT-GUARD™ Cerebral Embolic Protection (CEP) device, marking a major milestone in the clinical evaluation of this innovative technology.
